ANALYSIS OF THE BLEEDING AND THROMBOEMBOLIC RISK WITH CONCOMITANT USE OF ANTIPLATELET TREATMENT IN THE AMPLIFY TRIAL

Alan Cohen; Giancarlo Agnelli; H.R. Büller; Sayani Chaudhuri; Alexander Gallus; Gary E. Raskob; Philip Sanders; Jonathan P. Thompson; Juergen Weitz

doi:10.1016/j.cjca.2014.07.481

Related publications

Article1999

Oral anticoagulant treatment in patients with mechanical heart valves: how to reduce the risk of thromboembolic and bleeding complications

Suzanne C. Cannegieter, Marieke Torn, Frits R. Rosendaal

Journal of Internal Medicine

Article2021

Low bleeding and thromboembolic risk with continued dabigatran during cardiovascular interventions: the GLORIA-AF study

Sake J. van der Wall, Professor Gregory Lip, Christine Teutsch, Oskars Kalējs, Philippe Lyrer, Christian Hall, Sérgio Dubner, Hans‐Christoph Diener, Jonathan L. Halperin, Chang Sheng, Kenneth J. Rothman, Kristina Zint, Dongmei Zhai, Menno V. Huisman

Article2020

Regular Bleeding Risk Assessment Associated with Reduction in Bleeding Outcomes: The mAFA-II Randomized Trial

Yutao Guo, Deirdre A. Lane, Yundai Chen, Professor Gregory Lip

Article2019

Thromboembolic, bleeding, and mortality risks among patients with nonvalvular atrial fibrillation treated with dual antiplatelet therapy versus oral anticoagulants: A population-based study

Wallis C. Y. Lau, Ian Douglas, Ian Chi Kei Wong, Liam Smeeth, Professor Gregory Lip, Wai K. Leung, Chung‐Wah Siu, Bernard M.Y. Cheung, Michael Mok, Esther W. Chan

Article2017

Balancing thromboembolic and bleeding risk with non-vitamin K antagonist oral anticoagulants (NOACs): A systematic review and meta-analysis on gender differences

Marco Proietti, Paola Cheli, Stefania Basili, Michał Mazurek, Professor Gregory Lip